Ranitidine

Ranitidine is a competitive, reversible histamine H2 receptor antagonist, a class of drugs that lower the secretion of gastric acid ^[1]. It was first synthesized in England in 1977 by the chemist John Bradshaw at Glaxo's laboratories and grew out of a deliberate effort to design an improved successor to the earlier H2 blocker cimetidine, replacing that molecule's imidazole ring with a furan-based structure ^[1]. Entering use in the early 1980s under the brand name Zantac, it had become the world's best-selling prescription drug by the late 1980s.

Medically, ranitidine has been used for heartburn, gastric and duodenal ulcers, gastroesophageal reflux disease, erosive esophagitis, and the acid oversecretion of Zollinger-Ellison syndrome, as well as for preventing stress ulcers in seriously ill patients ^[1]. Studies have compared its speed of acid suppression with that of other agents such as famotidine ^[1]. As with other acid-suppressing drugs, research has associated its use with a higher risk of certain infections, including gastrointestinal infections and pneumonia in children and Clostridioides difficile infection in adults ^[2][3].

Beginning in 2019, testing detected N-nitrosodimethylamine (NDMA), classified as a probable human carcinogen, in ranitidine products, and the impurity was found to increase as the drug degraded over time ^[4]. In 2020 the United States Food and Drug Administration requested that all ranitidine products be withdrawn from the market, and European regulators suspended them as well ^[4]. Later laboratory work traced much of the NDMA formation to defects in the drug's crystal structure and showed that improved crystallization could suppress it, informing reformulated versions ^[4]. The drug had previously been available both by prescription and over the counter, in oral tablets, syrups, and injectable forms.

Ranitidine is a prescription and formerly over the counter medicine that has been withdrawn in many countries because of NDMA contamination, a probable human carcinogen that increases with storage and temperature. As an H2 blocker its own side effects were usually mild; headache, constipation or diarrhea and dizziness, with rare reports of low platelet counts, liver irritation, breast enlargement and confusion in older adults or those with poor kidney function. The main modern concern is the impurity rather than the drug action, and current advice generally favors safer alternatives such as famotidine. Anyone still holding old ranitidine should not use it and should dispose of it properly.

Ranitidine's interactions come from raising gastric pH, not from enzyme inhibition, which is what separates it from cimetidine. It binds cytochrome P450 with roughly a tenth of cimetidine's affinity, so the theophylline, warfarin and phenytoin interactions that made cimetidine troublesome largely do not appear here.

The pH effect is substantial. Ketoconazole exposure fell by as much as 95 percent when ranitidine was given in a regimen holding gastric pH at 6 or above, and atazanavir and other acid-dependent drugs are impaired the same way. It runs in the other direction too: triazolam, midazolam and glipizide are absorbed more completely at higher pH, so sedation from a benzodiazepine or a glucose-lowering response can be larger than expected.

At high doses ranitidine also competes for renal tubular secretion and raises plasma procainamide and its N-acetyl metabolite, which is unlikely to matter at ordinary doses. Worth noting for context: ranitidine was withdrawn from most markets after NDMA contamination was found in the drug substance, so these interaction questions are now largely historical or belong to the agents that replaced it.

Checking a whole stack? Run it through interactions + stacks.

Ranitidine was discovered by scientists at Glaxo, in a research effort led by John Bradshaw, as the company sought a histamine H2 receptor antagonist that would improve upon the pioneering acid-reducer cimetidine. Introduced in 1981 under the brand name Zantac, it offered longer action and fewer drug interactions than its predecessor, and through aggressive development and marketing it became, by the late 1980s, one of the best-selling prescription medicines in the world.

For decades it was a mainstay treatment for heartburn, peptic ulcers, and gastroesophageal reflux, available both by prescription and over the counter. Its long run came to an abrupt end beginning in 2019, when testing revealed that the ranitidine molecule could form N-nitrosodimethylamine (NDMA), a probable human carcinogen, under certain storage and physiological conditions. Regulators including the United States Food and Drug Administration requested broad market withdrawals in 2020, ending the availability of most ranitidine products.

For most of its life ranitidine enjoyed an outstanding reputation as a safe, effective, and convenient remedy for acid-related complaints, so trusted that it became a household name through the Zantac brand and one of the first blockbuster drugs in pharmaceutical history. Clinicians relied on it for healing ulcers and controlling reflux, and patients valued its fast, dependable relief with a low burden of side effects during ordinary use.

Its enduring legacy is twofold: it demonstrated the commercial and therapeutic power of the H2-blocker concept, and its later downfall became a landmark case study in pharmaceutical quality and the chemistry of nitrosamine impurities. It is important to be clear that the NDMA problem was a contamination and stability issue intrinsic to the molecule, not a consequence of its acid-blocking action, and that closely related H2 blockers such as famotidine remain widely used. Ranitidine is remembered as a genuinely effective medicine undone by an unexpected chemistry flaw.